Adaptive Biotechnologies Corporation

ADPT Healthcare Diagnostics & Research

Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.

Revenue
−10.7%
EPS
−66.7%
Free cash flow
+201.9%

Quarter to September 2026, against a year earlier

26.96 0.25 +0.94%
Market cap
$4.3B
P/E
0.0×
Fwd P/E
−49.4×
Dividend yield
—
F-score
6/9
Altman Z
2.08
Beneish M
−2.44
Dividend safety
n/a

Adaptive Biotechnologies Corporation (ADPT) P/E ratio

Alert me on P/E ratio

Adaptive Biotechnologies Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
29 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
WGS GeneDx Holdings Corp. compare n/m
RDNT RadNet, Inc. compare n/m
NEO NeoGenomics, Inc. compare n/m
GRAL GRAIL, Inc. compare n/m
ADPT Adaptive Biotechnologies Corporation n/m
VCYT Veracyte, Inc. compare 15.2×
SHC Sotera Health Company compare 26.3×
CDNA CareDx, Inc. compare 30.9×
BLLN BillionToOne, Inc. compare 88.7×
Diagnostics & Research industry median 34.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on ADPT